(Q34368537)

English

The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects (English)

1 reference

Europe PubMed Central

1 August 2017

chronic obstructive pulmonary disease

1 reference

based on heuristic

inferred from title

umeclidinium bromide

1 reference

ChEBI release 2020-05-28

author name string

Gregory J Feldman

1

1 reference

Europe PubMed Central

1 August 2017

Anton Edin

2

1 reference

Europe PubMed Central

1 August 2017

publication date

3 September 2013

1 reference

Europe PubMed Central

1 August 2017

Therapeutic advances in respiratory disease

1 reference

Europe PubMed Central

1 August 2017

7

1 reference

Europe PubMed Central

1 August 2017

6

1 reference

Europe PubMed Central

1 August 2017

311-319

1 reference

Europe PubMed Central

1 August 2017

Exacerbations of chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

Patient adherence in COPD.

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

β(2) -adrenoceptor agonists: current and future direction

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

β2-agonist therapy in lung disease

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

Clinical pharmacokinetics of salmeterol

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

A unified front against COPD: clinical practice guidelines from the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European Respiratory Society.

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

Medication adherence issues in patients treated for COPD.

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

Comparison of indacaterol with tiotropium or twice-daily long-acting β -agonists for stable COPD: a systematic review

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

Long-term Treatment Benefits With Tiotropium in COPD Patients With and Without Short-term Bronchodilator Responses

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD.

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.

1 reference

https://api.crossref.org/works/10.1177%2F1753465813499789

21 January 2018

Identifiers

10.1177/1753465813499789

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34368537&oldid=1548909011"